Trial Profile

A double-blind, placebo-controlled multicenter phase II/III study of AKS-452

Status: Completed

Phase of Trial: Phase II/III

Latest Information Update: 08 Nov 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AKS-452 (Primary)
Indications COVID 2019 infections
Focus Registrational; Therapeutic Use
Sponsors Akston Biosciences

Most Recent Events

01 Nov 2022 According to an Akston Biosciences media release, the positive results from that study have been submitted as part of an Emergency Use Application in India.
01 Nov 2022 Status changed from recruiting to completed, according to an Akston Biosciences media release.
24 Jun 2022 Results published in an Akston Biosciences Media Release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com